





Introduction: T-helper type 1 (Th1) cells play an important role in inflammation in the adaptive immune system. Th1 is indicated in the pathogenesis of subclinical atherosclerosis and several chronic inflammatory diseases. If decreasing Th1 levels could result in decreased inflammation, a search for modifiable risk factors is of great public health significance. Animal studies have shown intervention with n-3 PUFAs reduced Th1 cells. However, the association of Th1 and n-3 PUFAs has not been investigated in humans. We hypothesized that n-3 PUFAs have an inverse association with Th1 cells in MESA. 
Methods: We included 895 MESA participants from the Multi-Ethnic Study of Atherosclerosis with data on n-3 PUFAs at exam 1 (2000-02) and Th1 cells at exam 4 (2005-07) (age 61±10 years, 467 women, 396 Caucasians, 219 Hispanics, 185 African-Americans, 95 Chinese-Americans). Th1 cells were measured by flow cytometry as a percentage of CD4+ lymphocytes that were interferon-γ+ (%Th1). Plasma phospholipid n-3 PUFAs (% of total fatty acids), defined as the sum of eicosapentaenoic and docosahexaenoic acids, were measured by gas chromatography. Dietary intake of n-3 PUFAs was evaluated by food frequency questionnaire (N=847). Linear regression models were used to analyze prospective associations of n-3 PUFA with %Th1 adjusting for covariates. 
Results: Mean n-3 PUFA and %Th1 levels were 4.8 ± 2.1% and 15.9 ± 8.3%, respectively. n-3 PUFAs were not significantly associated with %Th1 (P value=0.937). The association remained non-significant after adjusting for covariates. Dietary intake of n-3 PUFAs also showed no significant association with %Th1. 
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T-helper 1 (Th1) cells play an important proinflammatory role in the adaptive immune system. Th1 cells are one of the Th cell subsets that differentiate from naive T (Th0) cells, via the T-cell polarization process1. Th1 cells stimulate and regulate signals to immune cells, and produces cytokines such as interferon (INF)-γ, tumor necrosis factor (TNF)-β, interleukin (IL)-12, and IL-181. These cytokines are involved in various inflammatory diseases. One example is atherosclerosis. INF-γ, the signature Th1 cytokine, is involved in the initiation, progression and rupture of plaques2. IL-12 and IL-18 are involved in plaque development as well ADDIN EN.CITE , . We reported that in the US general population, Th1 cells have significantly positive associations with subclinical atherosclerosis, i.e., intima media thickness of the carotid artery and coronary artery calcification ADDIN EN.CITE 4.Th1 cells are also associated with other chronic inflammatory diseases such as psoriasis ADDIN EN.CITE 5 and Crohn’s disease, and potentially type 1 diabetes6. 
Several factors are suggested to determine Th1 levels. These include age, genetic predisposition, and cytomegalovirus (CMV) levels ADDIN EN.CITE , . However, it is unknown whether interventions in modifiable factors, such as lifestyle factors, could lead to change in Th1 levels. If decreasing Th1 levels could result in decreased inflammation, a search for modifiable risk factors is of great significance.
Some studies imply the possibility that long chain n-3 polyunsaturated fatty acids (PUFAs), namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), decrease T-cell proliferation and Th1 production8. In vitro experiments have shown that EPA and DHA can inhibit T-cell proliferation, and decrease the production of a Th1 cytokine, IL-29. Reduced T-cell proliferative responses and suppression of Th1 cytokines have also been reported in animals that were fed high amounts of EPA or DHA10. n-3 PUFAs have shown to decrease T-cell proliferation, measured by [3H]thymidine incorporation following stimulation with T cell mitogens in peripheral blood mononuclear cell (PBMC) cultures of humans as well ADDIN EN.CITE , . Possible mechanisms of n-3 PUFAs on T cell proliferation include changes in membrane order, altered patterns of eicosanoid production and modification of early signal transduction events8. However, these studies have not evaluated different phenotypes of T cells. 






MESA is a longitudinal epidemiological study of men and women to investigate the prevalence and progression of subclinical cardiovascular disease (CVD). Total of 6,814 Caucasian, African Americans, Hispanic Americans, and Chinese Americans, aged 45 to 84 free of known cardiovascular diseases were recruited at six field centers (Baltimore, MD; Chicago, IL; Los Angeles, CA; Minneapolis, MN; New York, NY; Winston-Salem, NC) during the baseline exam (exam 1) in 2000-2002. During exam 4 (2005-2007), cellular phenotypes were measured for the subset of about 1000 participants chosen at random for specialized biomarker analysis through the MESA-Inflammation ancillary study. Details of the parent MESA study and MESA-inflammation have been described elsewhere ADDIN EN.CITE , . Among MESA-Inflammation participants, we excluded those without Th1 data (N=14) and plasma n-3 PUFA data (N=21), resulting in 895 participants for this analysis. Additional analysis replacing dietary intake for plasma n-3 PUFA was conducted. For this analysis, we excluded those without Th1 data (N=14) and dietary intake of n-3 PUFAs data (N=70), resulting in 847 participants. A subanalysis with CMV serology, a significant determinant of Th1 ADDIN EN.CITE 4, was also performed. Due to the high missing number of CMV serology (N=181 for plasma and N=183 for dietary n-3 PUFAs), the subanalysis had 714 participants for plasma and 664 participants for dietary n-3 PUFA data.  
2.2	n-3 PUFA
Plasma and dietary intake of n-3 PUFAs were assessed at exam 1. Phospholipid fatty acids were extracted from EDTA plasma using the chloroform/methanol method14. Fatty acids were expressed as a percent of the total phospholipid fatty acids. In our study, we defined plasma n-3 PUFAs as the total of EPA and DHA. We did not include docosapentaenoic acid (DPA), because dietary DPA accounted for only a small fraction of dietary n-3 PUFAs, and the results were essentially the same when DPA was included in both dietary and plasma data. The representative coefficients of variation (CV) values obtained from intra-laboratory quality control (N=20) were 3.3% for plasma EPA and 2.7% for plasma DHA ADDIN EN.CITE 15. Dietary intake of n-3 PUFA was assessed by using a self-administered food frequency questionnaire (FFQ) described in detail elsewhere ADDIN EN.CITE 16. In brief, usual dietary intake over the previous year was assessed with a modified Block-style 120-item FFQ. Consumption frequency and serving size of each food was assessed. Characteristic of the Block FFQ design, serving sizes were quantified as small, medium or large, with corresponding weights (g) imputed according to National Health and Nutrition Examination Survey data. Nutrients were calculated for each FFQ line item according to a weighted recipe using the Nutrition Data System for Resarch (NDS0R database; Nutrition Coordinating Center, Minneapolis, MN, USA) ADDIN EN.CITE 16.  Dietary and plasma n-3 PUFA were not highly, but significantly correlated (Pearson correlation coefficient: 0.248, P-value: <0.001).
2.3	Flow-Cytometric Analyses of T-Cell Phenotypes
T-cell phenotypes including Th1 cells were assessed as a part of MESA-Inflammation, whose design, methods, and quality assurance/quality control program have been published ADDIN EN.CITE 4  ADDIN EN.CITE 17. In brief, Th1 cells were measured from peripheral blood mononuclear cells (PBMCs), which were stimulated with phorbol 12-myristate 13-aceate (40 ng/mL), ionomycin (1μg/mL), and brefeldin A (10μg/mL) (Sigma-Aldrich, St. Louis, MO) for 3 hours at 37°C and labeled with R-phycoerythrin-cyanine dye Cy5-conjugated anti-CD4 (BD Biosciences, San Jose, CA). Cells were fixed with 2% paraformaldehyde, permeabilized with 0.1% saponin, and incubated with fluorescein isothiocyanate anti-IFN-γ and PE anti-IL-4 (Sigma-Aldrich, St. Louis, MO). Unstimulated PBMCs that underwent the same protocol without the addition of activators were used as negative controls. Th1 cells were expressed as the percentage of CD4+ lymphocytes that were INF-γ+ (%Th1: CD4+IFN-γ+). The CV value for %Th1 was 26.25%.
2.4	Other covariates
Standardized questionnaires were used to obtain information on demographic and major lifestyle variables at exam 1. These included age, gender, ethnicity, education level (≥high school graduate), smoking (never, past, or current), physical activity (sum of intentional exercise in metabolic equivalent-min/week), diabetes mellitus (DM) status (normal/impaired fasting glucose (IFG)/DM), hypertension, and current mediation use. Hypertension was defined as systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg or use of hypertension medication. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters-squared (kg/m2). IL-6, CMV serology, and plasma lipid concentrations were assessed at exam 1. Twelve-hour fasting blood was drawn, and serum and EDTA-anticoagulant tubes were collected and stored at -70°C using a standardized protocol ADDIN EN.CITE 13. Interleukin-6 (IL-6) was measured using the quantitative sandwich enzyme immunoassay technique of enzyme-linked immunosorbent assay assays (Quantikine HS Human IL-6 Immunoassay). CMV serology was measured by indirect enzyme immunoassay (DiaMedex Corp. Miami, FL) and reported as ELISA units (EU/ml). Total cholesterol and triglycerides were measured on a Roche Modular P Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN). HDL cholesterol was measured using the cholesterol oxidase method (Roche Diagnostics) after precipitation of non-HDL cholesterol with magnesium/dextran. LDL cholesterol was calculated in plasma specimens having a triglyceride value <400 mg/dl using the formula of Friedewald et al18. Season (January to March/ April to June/ July to September/ October to December), a significant determinant of Th1 ADDIN EN.CITE 4, was assessed at exam 4, concurrent with the assessment of Th1.
2.5	Statistical Analyses
Means±SD or Pearson correlations were used to describe the associations between %Th1 or n-3 PUFA and other variables. Linear regression models were used to assess the association of n-3 PUFA with %Th1 adjusting for covariates. Serum and dietary n-3 PUFA were assessed separately. Three sets of models were built. Model 1 assessed %Th1 adjusted for variables that are multivariately associated with %Th1 based on previous literature ADDIN EN.CITE 4 (age, sex, and season), race, and site. Model 2 included variables in Model 1 and variables that are univariately associated with %Th1 (smoking, physical activity, education, BMI, statin use, IL-6, TG, HDL-C, TC, and hypertension). Model 3 included variables in Model 2 and CMV. Model 3 was analyzed among participants with CMV serology (N=714 for plasma n-3 PUFA and N=664 for dietary intake of n-3 PUFA). All analyses were tested two-sided, with a P-value of <0.05 considered statistically significant. SAS version 9.4 (SAS Institute, Inc., Cary, NC) was used to perform statistical analyses.
3.0 	RESULTS
The mean (SD) age of participants was 61 (10) years old with a BMI of 28.5 (5.5) kg/m2. Women constituted 52%, and the ethnic distributions were 44% Caucasian, 24% Hispanic, 21% African-American, and 11% Chinese-American. The mean (SD) of plasma n-3 PUFA and %Th1 levels were 4.85 (2.07) and 15.9 (8.3), respectively. The mean (SD) of dietary intake of n-3 PUFA was 0.13 (0.13) mg/day (Table 1). 
In univariate analysis, %Th1 was significantly associated with ethnicity, BMI, education, IL-6, and CMV serology. However, %Th1 was not significantly associated with either plasma or dietary n-3 PUFA (P=0.937 and 0.889, respectively. Table 2). Plasma n-3 PUFAs were significantly associated with gender, BMI, smoking history, physical activity, education, HDL-cholesterol, triglycerides, statin use, IL-6 and season (Table 3). Dietary n-3 PUFAs were similarly significantly associated with gender, BMI, education, and statin use. However, unlike plasma n-3 PUFAs, dietary n-3 PUFAs were significantly associated with age and total cholesterol (data not shown).     
Table 4 shows the associations of plasma n-3 PUFA and %Th1 adjusted for covariates. The insignificant associations did not change after adjustment for covariates in models 1, and 2. Plasma n-3 PUFA and %Th1 was not significantly associated even in the final model with limited number of participants adjusted for CMV. 
The results were consistent when substituting dietary intake of n-3 PUFA for plasma n-3 PUFA and adjusting for other covariates in models 1, 2, and 3 (Table 5). The results were also consistent when excluding participants with fish oil supplements (N=867 for plasma and N=819 for dietary n-3 PUFA, data not shown).
4.0 	DISCUSSION
In this study of the US general population, neither plasma nor dietary intakes of n-3 PUFA were significantly associated with %Th1. The nonsignificant association remained after adjusting for various confounding factors. To the best of our knowledge, this is the first study to investigate the association of n-3 PUFA and %Th1 in the general population. 
Anti-inflammatory properties of n-3 PUFAs have been described in patients with inflammatory diseases, yet the associations of n-3 PUFAs with Th1 have very little been investigated. Supplementation with n-3 PUFAs decreased serum TNF-α concentrations in patients with rheumatoid arthritis ADDIN EN.CITE 19. In patients with inflammatory bowel disease (i.e., Crohn’s disease and ulcerative colitis), supplementation with DHA and/or EPA has resulted in improvement in symptoms and decrease in medication use and relapse. Supplementation with EPA and DHA has also improved symptoms of patients with psoriasis20. Among patients with psoriasis and atopic dermatitis, 6g of EPA and DHA significantly decreased the expression of IL-2 receptor ADDIN EN.CITE 21. It is possible that the effects of n-3 PUFAs on cytokines are via Th1. However, the specific effects on Th1 have not been investigated.
On the other hand, some studies report that n-3 PUFAs supplementation change Th1 in some special conditions. In cancer-bearing state, Th1/Th2 balance shifts toward Th2 dominance ADDIN EN.CITE 22. Perioperative supplementation with 3g/d of n-3 PUFA has decreased Th1/Th2 balance among patients undergoing surgery for colorectal cancer ADDIN EN.CITE 22. As for colorectal cancer, immunomodulatory effects of n-3 PUFAs may even influence the chronic inflammation that is associated with the development of colorectal cancer ADDIN EN.CITE 23. Th1/Th2 balance is also altered by surgical stress. Perioperative n-3 PUFAs supplementation among patients undergoing pancreaticoduodenectomy also modulated Th1/Th2 differentiation and significantly reduced the rate of infectious complications (i.e., stress-induced immunosuppression) ADDIN EN.CITE 24. Among women at high risk of having babies with allergies, supplementation with n-3 PUFAs was significantly associated with decreased Th1 in babies ADDIN EN.CITE 25. These studies imply that at least among those in certain conditions, n-3 PUFAs supplementation may decrease Th1.
Whether n-3 PUFAs have effect on Th1 in the general population is uncertain. In a systematic review of 10 studies of healthy individuals, n-3 PUFA supplementation did not significantly affect cytokines or chemokines ADDIN EN.CITE 26. Among these studies, five studies measured signature Th1 cytokines, notably TNF-α and IFN-γ. However, none of the studies showed change in TNF-α and IFN-γ with 0.3-4.4 g/day of n-3 PUFAs ADDIN EN.CITE 27-31. Although the specific effect on Th1 have not been investigated, it is unlikely that n-3 PUFAs have changed Th1 levels in these studies of healthy individuals. However, one interesting study of elite paddlers showed that TNF-α and IFN-γ decreased significantly after supplementation of 1.2g DHA and 2.4 g EPA/d. Although this was a small study of 22 participants in total, consumption of n-3 PUFAs with intense exercise may reduce TNF-α and IFN-γ ADDIN EN.CITE 32. n-3 PUFAs may affect Th1 or cytokine levels of healthy individuals differently by conditions or populations. 
Animal studies show that n-3 PUFAs supplementation may decrease Th1. In several studies, mice that were fed n-3 PUFAs showed direct suppression of Th1 development ADDIN EN.CITE , . In another study of mice, n-3 PUFAs did not affect the percentage of Th1-positive cells, but the Th1 effector cell proliferative response to antigen, suggesting that the shift in the effector cell balance as a result of the direct suppression of Th1 may be the mechanism ADDIN EN.CITE 34. However, the extent the results can be applied to the human general population needs investigation. The amount of n-3 PUFAs necessary to have an effect in humans may be different. A dose of at least 2g/d of n-3 PUFA is suggested to be necessary to have immunomodulatory effects in humans HYPERLINK \l "_ENREF_8" \o "Calder, 2015 #2"  ADDIN EN.CITE <EndNote><Cite><Author>Calder</Author><Year>2015</Year><RecNum>2</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="d02f9fft0w9epgewfauxx5z4wzwt9f5e9552">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Calder, P. C.</author></authors></contributors><auth-address>Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK; Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: pcc@soton.ac.uk.</auth-address><titles><title>Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance</title><secondary-title>Biochim Biophys Acta</secondary-title></titles><periodical><full-title>Biochim Biophys Acta</full-title></periodical><pages>469-484</pages><volume>1851</volume><number>4</number><keywords><keyword>Cytokine</keyword><keyword>Eicosanoid</keyword><keyword>Inflammation</keyword><keyword>Lymphocyte</keyword><keyword>Macrophage</keyword><keyword>Resolvin</keyword></keywords><dates><year>2015</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0006-3002 (Print)&#xD;0006-3002 (Linking)</isbn><accession-num>25149823</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/25149823</url></related-urls></urls><electronic-resource-num>10.1016/j.bbalip.2014.08.010</electronic-resource-num></record></Cite></EndNote>8. Interaction with other nutrients could also be an issue ADDIN EN.CITE 35.
Similar to n-3 PUFAs, there are some studies that imply statins may reduce Th1. Statins are suggested to shift the Th1/Th2 balance toward a Th2-type response via direct or indirect influence on Th0 cells36. Several studies have investigated change in cytokines, as a marker of Th1 or Th2 in humans. Administration of statins in patients with rheumatoid arthritis decreased IFN-γ, synovial synthesis of IL-6 and IL-8, and prevented TNF-α-induced synoviocytes from proliferation36. Among patients with chronic heart failure, atorvastatin decreased the ratio of IFN-γ/IL-4, used as an estimated index of the Th1/Th2 profile ADDIN EN.CITE 37. There are implications that statins can be used to reduce symptoms of other inflammatory diseases, such as multiple sclerosis and systemic lupus erythematosus36. However, whether these effects are via Th1 or how much statins change Th1 levels are unknown. Moreover, satins may have differential effects on healthy individuals. In our analysis, n-3 PUFA was not significantly associated with %Th1 even after adjustment for statins in Model 2.
The strengths of our study include a large sample size with various ethnic groups. Many important variables were measured, which enabled adjustment with various confounding factors. We were able to confirm our results with both dietary and plasma n-3 PUFA data. Our study design enabled us to assess the prospective association of n-3 PUFA and Th1 in three years. 
There are limitations. Data on dietary n-3 PUFA may be subject to recall biases. Because this is an observational study, unmeasured confounding factors may exist. The CV value for %Th1 was high. 





Table 1. Description of participants 
Variable	Mean± SD or N(%)
Age, years	60.5±9.10
Male, N (%)	428 (48)
Ethnicity, N (%)	 
   Caucasian	396 (44)
   African American	185 (21)
   Hispanic American	219 (24)
   Chinese American	95 (11)
BMI, kg/m2	28.5±5.5
Smoking history, N(%)	 
    Never 	449 (50)
    Past	326 (37)
    Current	118 (13)
Physical activity , MET-min/week	6413±6764
≥High school graduate, N (%)	587 (66)
Diabetes, N (%)	 
    Normal	695 (78)
    Impaired fasting glucose	111 (12)
    Diabetes mellitus	88 (10)
Hypertension, N(%)	365 (41)
Lipids, mg/dl	 
    LDL-cholesterol	118±30
    HDL-cholesterol	50±14
    Total cholesterol	195±34
    Triglycerides	132±81




   January-March	399 (45)
   April-June	206 (23)
   July-September	47 (5)








Table 2. Unadjusted associations of %Th1 and other variables
Variable	Mean (SD) or Correlation Coefficient	P value
Age, years	-0.0223	0.420
Gender	 	 
   Female	15.9 (8.4)	0.975
   Male	15.9 (8.1)	
Ethnicity	 	 
   Caucasian	14.2 (7.4)	<0.001
   African American	17.1 (10.1)	
   Hispanic American	17.5 (7.6)	
   Chinese American	17.0 (7.6)	
BMI, kg/m2	0.1208	0.017
Smoking history	 	 
    Never 	15.8 (7.8)	0.189
    Past	15.5 (8.7)	
    Current	17.4 (8.8)	
Physical activity, MET-min/week	0.00007	0.117
Education	 	 
   <High school graduate	17.2 (8.0)	<0.001
   ≥High school graduate	15.2 (8.3)	
Diabetes	 	 
    Normal	15.8 (8.4)	0.562
    Impaired fasting glucose	15.7 (7.4)	
    Diabetes mellitus	16.5 (8.5)	
Hypertension	 	 
   With hypertension	16.1 (8.2)	0.456
   Without hypertension	15.6 (8.4)	
Lipids, mg/dl	 	 
    LDL-cholesterol	-0.0124	0.179
    HDL-cholesterol	-0.0376	0.054
    Total cholesterol	-0.0142	0.080
    Triglycerides	0.0003	0.252
Statins	 	 
    With statin	15.9 (8.4)	0.663




   January - March	15.6 (8.4)	0.717
   April-June	16.4 (7.9)	
   July-September	17.5 (8.2)	







Table 3. Unadjusted associations of plasma n-3 PUFA and other variables
Variable	Mean (SD) or Correlation Coefficient	P value
Age, years	0.0007	0.309
Gender	 	 
   Female	5.06 (2.16)	0.002
   Male	4.62 (1.94)	
Ethnicity	 	 
   Caucasian	4.53 (1.85)	0.395
   African American	5.47 (2.06)	
   Hispanic American	4.14 (1.79)	
   Chinese American	6.61 (2.23)	
BMI, kg/m2	-0.052	<0.001
Smoking history	 	 
    Never 	5.17 (2.15)	<0.001
    Past	4.65 (1.97)	
    Current	4.15 (1.74)	
Physical activity , MET-min/week	-0.00003	0.004
Education	 	 
   <High school graduate	4.66 (2.06)	0.048
   ≥High school graduate	4.95 (2.07)	
Diabetes	 	 
    Normal	4.82 (2.04)	0.6861
    Impaired fasting glucose	5.02 (2.13)	
    Diabetes mellitus	4.83 (2.20)	
Hypertension	 	 
   With hypertension	4.92 (1.98)	0.3578
   Without hypertension	4.80 (2.12)	
Lipids, mg/dl	 	 
    LDL-cholesterol	-0.0019	0.404
    HDL-cholesterol	0.0123	0.012
    Total cholesterol	-0.0030	0.129
    Triglycerides	-0.0031	<0.001
Statins	 	 
    With statin	5.28 (2.36)	0.019




   January - March	4.95 (2.22)	0.016
   April-June	4.99 (2.06)	
   July-September	4.69 (1.91)	




Table 4. Association of plasma n-3 PUFA and %Th1






Model 1: Adjusted for age, sex, clinical site, race, season
Model 2: Model 1+ smoking, physical activity, education, BMI, statin use, IL-6, triglycerides,  
               HDL-cholesterol, total cholesterol, hypertension
Model 3: Model 2+ cytomegalovirus (analyzed among those with CMV data; N=714)


Table 5. Association of dietary n-3 PUFA and %Th1






Model 1: Adjusted for age, sex, clinical site, race, season
Model 2: Model 1+ smoking, physical activity, education, BMI, statin use, IL-6, triglycerides, 
   HDL-cholesterol, total cholesterol, hypertension
Model 3: Model 2+ cytomegalovirus (analyzed among those with CMV data; N=664)
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